Concept Life Sciences, scientific Laboratory and consultancy group has acquired pharmaceutical analytical testing business Agenda1 Analytical Services Ltd (Agenda 1).

This marks its fifth acquisition since it was formed in July 2014.

Agenda 1 is a specialist contract analytical company delivering high quality analytical support to pharmaceutical, healthcare and medical device companies. Over the past year Concept Life Sciences has achieved an impressive organic growth rate and this deal is a prime example of how well-chosen partners can further expedite growth by extending capability.

Agenda 1 was established in 2006 by Dr Simon Bristow and Ian Siragher and quickly became a well-recognised laboratory working with a wide range of companies. Their focus on pharmaceutical and healthcare Industries led to them gaining MHRA accreditation in 2012 and their access to a wide range of GMP qualified equipment sets them apart in the industry.

Commenting on the deal, Concept Life Sciences CEO Alan Morgan said: ”Agenda1 has a very strong business model merging significant capability and skilled staff with a positive reputation. By combining innovative and unrestricted thinking they have successfully created a problem-solving flexibility that is invaluable to its customers. This approach is complementary to Concept Life Sciences’ established business base.”

Agenda 1 Managing Director, Ian Siragher will continue to lead the business said: “The timing of this acquisition is very positive as we have been expanding our range of services to better meet clients’ demands. The investment from Concept Life Sciences means we can not only continue to do this but expedite the process whilst benefiting from being part of a larger team.”

Other members of the founding team will remain in place including Dr Simon Bristow (Technical Director and co-founder), Dr Caroline German (Site Operations Director) and Dr Eleanor Hurst (Head of Chromatography).

Michael Fort, Concept Life Sciences Executive Chairman followed: “Organic growth is vital to ensure our business is built on a solid base which supports complementary, well-integrated services. We are committed to growing the business in this way and our growth figures full support this. However, in order to complement this success we continue to look for acquisition targets that further expand our operational capabilities and better address our client’s need. Not least because such acquisitions not only expand our services but also enable us to stay fresh in terms of our approach and thinking. It is this that will enable us to really differentiate ourselves in the markets in which we operate.”

Concept Life Sciences is supported by Equistone Partners Europe.

more about concept life sciences